

Hemostats Market by Type (Thrombin, Oxidized Regenerated Cellulose, Combination, Gelatin, Collagen), Formulation (Matrix & Gel, Sheet & Pad, Sponge, Powder), Application (Orthopedic, Neurological, Cardiovascular Surgery), Region - Global Forecast to 2028

<https://marketpublishers.com/r/H21D40D9390EN.html>

Date: October 2023

Pages: 223

Price: US\$ 4,950.00 (Single User License)

ID: H21D40D9390EN

Abstracts

The hemostats market is valued at an estimated USD 2.7 billion in 2023 and is projected to reach USD 3.7 billion by 2028 at a CAGR of 6.7% during the forecast period. The geriatric population represents a demographic segment with a rising demand for surgical procedures, thus underscoring the critical need for hemostatic agents in modern healthcare. Advancing age brings an increased susceptibility to a multitude of medical conditions and chronic diseases, often necessitating surgical interventions to sustain or enhance the overall quality of life. These surgical interventions span a wide spectrum, encompassing orthopedic joint replacements, intricate cardiac procedures, and complex gastrointestinal surgeries. Given the physiological transformations inherent to aging, including diminished tissue elasticity and heightened vulnerability to hemorrhages, the precise and efficient utilization of hemostatic agents assumes paramount significance in the surgical care of elderly patients. As the global geriatric population continues its steady expansion, the requirement for hemostats is anticipated to amplify proportionally, thus emphasizing their indispensable role in addressing the nuanced healthcare needs of elderly individuals undergoing surgical treatments.

“Combination hemostats segment accounted for the highest growth rate in the hemostats market, by type, during the forecast period.”

The hemostats market is bifurcated into oxidized regenerated cellulose-based hemostats, thrombin-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats on the basis of type. The combination hemostats segment in the hemostats market is experiencing substantial growth. Combination hemostats are often more effective at achieving hemostasis than single-agent hemostats. This is because they combine the strengths of different types of hemostats.

“Sponge hemostats segment accounted for the highest growth rate in the hemostats market, by formulation, during the forecast period.”

The global hemostats market is bifurcated into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. The sponge hemostats segment is currently witnessing the highest growth rate within the hemostats market. Market growth can largely be attributed to the growing acceptance of these formulations by end users due to the various advantages associated with them.

“Asia Pacific: The fastest-growing region hemostats market”

The global hemostats market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to witness the highest growth during the forecast period. Emerging countries in this region are witnessing growth in their GDPs and a significant rise in disposable income levels. This has led to increased healthcare spending by a larger population base. Other factors such as the increasing incidence & prevalence of chronic diseases, increasing burden of surgical procedures, healthcare infrastructure modernization, and the rising penetration of cutting-edge technologies (especially in rural areas) in Asia Pacific countries are also expected to provide significant growth opportunities for hemostats companies in this region. Also, other factors contributing to the growth include government efforts to increase awareness about the management of diseases and the increasing number of hospitals and clinics in India and China. The healthcare expenditure in Asian countries has also increased drastically. Growth in healthcare expenditure serves to increase the purchasing power of healthcare providers and stimulate the adoption of advanced medical/surgical supplies, including hemostats, in the region.

The break-up of the profile of primary participants in the hemostats market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%

The key players in this market are Johnson & Johnson (US), Baxter International (US), Pfizer Inc. (US), B. Braun SE (Germany), Becton, Dickinson and Company (US), Teleflex Incorporated (US), Medtronic Plc (Ireland), Hemostasis, LLC (US), Stryker Corporation (US), Integra LifeSciences (US), Advanced Medical Solutions Group Plc (UK), Samyang Holdings Corporation (South Korea), Marine Polymer Technologies, Inc. (US), GELITA MEDICAL GmbH (Germany), Dilon Technologies, Inc. (US), Betatech Medical (Turkey), Meril Life Sciences Pvt. Ltd. (India), BioCer Entwicklungs-GmbH (Germany), Unilene (US), Katsan Medical Devices (Turkey), Tricol Biomedical (US), 3-D Matrix Medical Technology (Japan), Hemostat Medical GmbH (Germany), Medtrade Products Limited (UK), and Altaylar Medical (Turkey).

Research Coverage:

This research report categorizes the hemostats market by type (thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats), formulation (orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, reconstructive surgery, and gynecological surgery, and other surgical applications), application (matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the hemostats market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent developments associated with the hemostats market. Competitive analysis of upcoming startups in the hemostats market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall hemostats market

and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (growing volume of surgical procedures performed, rising focus on R&D, and rising focus on effective blood loss management in patients during surgeries), restraints (side effects and allergic reactions associated with hemostats), opportunities (growth opportunities in emerging economies and growing number of hospitals), and challenges (stringent regulatory framework, dearth of skilled personnel for effective use of hemostats, and high cost of hemostats) influencing the growth of the hemostats market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the hemostats market.

Market Development: Comprehensive information about lucrative markets – the report analyses the hemostats market across varied regions.

Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the hemostats market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Johnson & Johnson (US), Baxter International (US), Pfizer Inc. (US), B. Braun SE (Germany), and Becton, Dickinson and Company (US), among others in the hemostats market strategies

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
 - 1.2.1 INCLUSIONS & EXCLUSIONS
- 1.3 STUDY SCOPE
 - 1.3.1 HEMOSTATS MARKET
 - 1.3.2 GEOGRAPHIC SCOPE
 - 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY
- 1.5 LIMITATIONS
- 1.6 STAKEHOLDERS
- 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
- 2.2 RESEARCH APPROACH
 - FIGURE 1 HEMOSTATS MARKET: RESEARCH DESIGN METHODOLOGY
 - 2.2.1 SECONDARY DATA
 - 2.2.1.1 Key data from secondary sources
 - 2.2.2 PRIMARY DATA
 - 2.2.2.1 Primary sources
 - 2.2.2.2 Key data from primary sources
 - 2.2.2.3 Key industry insights
 - 2.2.2.4 Breakdown of primary interviews
 - FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
 - FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- 2.3 MARKET SIZE ESTIMATION
 - 2.3.1 BOTTOM-UP APPROACH
 - 2.3.1.1 Approach 1: Company revenue estimation approach
 - FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
 - 2.3.1.2 Approach 2: Presentations of companies and primary interviews
 - 2.3.1.3 Growth forecast

2.3.1.4 CAGR projections

FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS

2.3.2 TOP-DOWN APPROACH

FIGURE 6 HEMOSTATS MARKET: TOP-DOWN APPROACH

2.4 MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 7 DATA TRIANGULATION METHODOLOGY

2.5 MARKET SHARE ANALYSIS

2.6 STUDY ASSUMPTIONS

2.7 GROWTH RATE ASSUMPTIONS

2.8 RISK ASSESSMENT

2.8.1 RISK ASSESSMENT: HEMOSTATS MARKET

2.9 RECESSION IMPACT

3 EXECUTIVE SUMMARY

FIGURE 8 HEMOSTATS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)

FIGURE 9 HEMOSTATS MARKET, BY FORMULATION, 2023 VS. 2028 (USD MILLION)

FIGURE 10 HEMOSTATS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)

FIGURE 11 HEMOSTATS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

4.1 HEMOSTATS MARKET OVERVIEW

FIGURE 12 GROWING NEED TO MANAGE BLOOD LOSS IN PATIENTS DURING SURGICAL PROCEDURES TO DRIVE MARKET GROWTH

4.2 HEMOSTATS MARKET SHARE, BY TYPE, 2023 VS. 2028

FIGURE 13 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS TO CONTINUE TO DOMINATE MARKET IN 2028

4.3 HEMOSTATS MARKET SHARE, BY FORMULATION, 2023 VS. 2028

FIGURE 14 MATRIX & GEL HEMOSTATS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD

4.4 HEMOSTATS MARKET SHARE, BY APPLICATION, 2023 VS. 2028

FIGURE 15 ORTHOPEDIC SURGERY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD

4.5 HEMOSTATS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN HEMOSTATS MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 17 HEMOSTATS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Growing volume of surgical procedures performed

TABLE 1 TOTAL NUMBER OF KNEE REPLACEMENTS, 2021

TABLE 2 TOTAL NUMBER OF CORONARY ARTERY BYPASS GRAFT PROCEDURES, 2021

5.2.1.2 Rising focus on R&D

5.2.1.3 Rising focus on effective blood loss management in patients during surgeries

5.2.2 RESTRAINTS

5.2.2.1 Side effects and allergic reactions associated with hemostats

5.2.3 OPPORTUNITIES

5.2.3.1 Growth opportunities in emerging economies

TABLE 3 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD)

5.2.3.2 Growing number of hospitals

5.2.4 CHALLENGES

5.2.4.1 Stringent regulatory framework

5.2.4.2 Dearth of skilled personnel for effective use of hemostats

5.2.4.3 High cost of hemostats

5.3 PRICING ANALYSIS

5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS

TABLE 4 INDICATIVE PRICING FOR HEMOSTATS

5.3.2 AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION

TABLE 5 AVERAGE SELLING PRICE OF HEMOSTATS

5.4 VALUE CHAIN ANALYSIS

FIGURE 18 VALUE CHAIN ANALYSIS OF HEMOSTATS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES

5.5 SUPPLY CHAIN ANALYSIS

FIGURE 19 HEMOSTATS MARKET: SUPPLY CHAIN ANALYSIS

5.6 PATENT ANALYSIS

FIGURE 20 PATENT ANALYSIS FOR HEMOSTATS (JANUARY 2013–DECEMBER 2022)

5.6.1 LIST OF MAJOR PATENTS

5.7 TRADE ANALYSIS

5.7.1 TRADE ANALYSIS FOR HEMOSTATS

TABLE 6 IMPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 7 EXPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018–2022 (USD MILLION)

5.8 ECOSYSTEM ANALYSIS

FIGURE 21 HEMOSTATS MARKET: ECOSYSTEM ANALYSIS

5.8.1 HEMOSTATS MARKET: ROLE IN ECOSYSTEM

5.9 PORTER'S FIVE FORCES ANALYSIS

TABLE 8 HEMOSTATS MARKET: PORTER'S FIVE FORCES ANALYSIS

5.9.1 THREAT OF NEW ENTRANTS

5.9.2 THREAT OF SUBSTITUTES

5.9.3 BARGAINING POWER OF SUPPLIERS

5.9.4 BARGAINING POWER OF BUYERS

5.9.5 INTENSITY OF COMPETITIVE RIVALRY

5.10 REGULATORY LANDSCAPE

TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.10.1 NORTH AMERICA

5.10.1.1 US

TABLE 13 CLASSIFICATION OF MEDICAL DEVICES BY US FDA

FIGURE 22 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES

5.10.1.2 Canada

FIGURE 23 APPROVAL PROCESS FOR CLASS III MEDICAL DEVICES IN CANADA

5.10.2 EUROPE

FIGURE 24 CE APPROVAL PROCESS IN EUROPE FOR HEMOSTATS

5.10.3 ASIA PACIFIC

5.10.3.1 Japan

TABLE 14 CLASSIFICATION OF MEDICAL DEVICES AND REVIEWING BODY IN JAPAN

5.10.3.2 China

TABLE 15 NMPA MEDICAL DEVICES CLASSIFICATION

5.10.3.3 India

5.11 TECHNOLOGY ANALYSIS

5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

FIGURE 25 REVENUE SHIFT IN HEMOSTATS MARKET

6 HEMOSTATS MARKET, BY TYPE

6.1 INTRODUCTION

TABLE 16 HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 17 HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

6.2 PRIMARY NOTES

6.2.1 KEY PRIMARY INSIGHTS

6.3 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS

6.3.1 GROWING AVAILABILITY OF ORC-BASED HEMOSTATIC AGENTS ACROSS UNTAPPED MARKETS TO DRIVE GROWTH

TABLE 18 MAJOR PRODUCTS IN OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET

TABLE 19 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 20 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)

6.4 THROMBIN-BASED HEMOSTATS

6.4.1 DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT GROWTH

TABLE 21 MAJOR PRODUCTS IN THROMBIN-BASED HEMOSTATS MARKET

TABLE 22 THROMBIN-BASED HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 23 THROMBIN-BASED HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)

6.5 COMBINATION HEMOSTATS

6.5.1 ADVANCEMENTS IN COMBINATION MATERIALS TO PROPEL MARKET GROWTH

TABLE 24 MAJOR PRODUCTS IN COMBINATION HEMOSTATS MARKET

TABLE 25 COMBINATION HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 26 COMBINATION HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)

6.6 GELATIN-BASED HEMOSTATS

6.6.1 HIGH ELASTICITY OFFERED BY GELATIN-BASED HEMOSTATS TO BOOST

DEMAND

TABLE 27 MAJOR PRODUCTS IN GELATIN-BASED HEMOSTATS MARKET

TABLE 28 GELATIN-BASED HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 29 GELATIN-BASED HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)

6.7 COLLAGEN-BASED HEMOSTATS

6.7.1 LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION TO PROMOTE ADOPTION OF COLLAGEN-BASED HEMOSTATS

TABLE 30 MAJOR PRODUCTS IN COLLAGEN-BASED HEMOSTATS MARKET

TABLE 31 COLLAGEN-BASED HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 32 COLLAGEN-BASED HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)

6.8 OTHER HEMOSTATS

TABLE 33 OTHER HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 34 OTHER HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)

7 HEMOSTATS MARKET, BY FORMULATION

7.1 INTRODUCTION

TABLE 35 HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION)

TABLE 36 HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION)

7.2 MATRIX & GEL HEMOSTATS

7.2.1 ABILITY OF MATRIX & GEL HEMOSTATS TO ENHANCE PLATELET AGGREGATION TO BOOST MARKET

TABLE 37 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 38 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)

7.3 SHEET & PAD HEMOSTATS

7.3.1 ABILITY TO CUT SHEET & PAD HEMOSTATS INTO ANY SHAPE OR SIZE TO FUEL ADOPTION

TABLE 39 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 40 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)

7.4 SPONGE HEMOSTATS

7.4.1 GROWING ACCEPTANCE OF SPONGE HEMOSTATS TO FUEL UPTAKE

TABLE 41 SPONGE HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 42 SPONGE HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)

7.5 POWDER HEMOSTATS

7.5.1 ABILITY TO SPRAY POWDER FORMULATIONS DIRECTLY ON WOUNDS TO FUEL DEMAND

TABLE 43 POWDER HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 44 POWDER HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)

8 HEMOSTATS MARKET, BY APPLICATION

8.1 INTRODUCTION

TABLE 45 HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION)

TABLE 46 HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION)

8.2 PRIMARY NOTES

8.2.1 KEY PRIMARY INSIGHTS

8.3 ORTHOPEDIC SURGERY

8.3.1 INCREASING INCIDENCE OF SPORTS INJURIES TO SUPPORT MARKET GROWTH

TABLE 47 NUMBER OF KNEE & HIP REPLACEMENTS, 2021

TABLE 48 HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2018–2021 (USD MILLION)

TABLE 49 HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2022–2028 (USD MILLION)

8.4 GENERAL SURGERY

8.4.1 INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE GROWTH

TABLE 50 TOTAL NUMBER OF INGUINAL HERNIA REPAIR PROCEDURES, 2021

TABLE 51 HEMOSTATS MARKET FOR GENERAL SURGERY, BY REGION, 2018–2021 (USD MILLION)

TABLE 52 HEMOSTATS MARKET FOR GENERAL SURGERY, BY REGION, 2022–2028 (USD MILLION)

8.5 NEUROLOGICAL SURGERY

8.5.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH

TABLE 53 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY REGION,

2018–2021 (USD MILLION)

TABLE 54 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY REGION,
2022–2028 (USD MILLION)

8.6 CARDIOVASCULAR SURGERY

8.6.1 RISING PREVALENCE OF CVD TO DRIVE ADOPTION OF HEMOSTATS

TABLE 55 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY
REGION, 2018–2021 (USD MILLION)

TABLE 56 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY
REGION, 2022–2028 (USD MILLION)

8.7 RECONSTRUCTIVE SURGERY

8.7.1 GROWING NUMBER OF COSMETIC SURGERIES TO SUPPORT MARKET
GROWTH

TABLE 57 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY
REGION, 2018–2021 (USD MILLION)

TABLE 58 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY
REGION, 2022–2028 (USD MILLION)

8.8 GYNECOLOGICAL SURGERY

8.8.1 GROWING USE OF HEMOSTATS IN C-SECTION PROCEDURES TO
CONTROL SURGICAL BLEEDING TO SUPPORT GROWTH

TABLE 59 HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY REGION,
2018–2021 (USD MILLION)

TABLE 60 HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY REGION,
2022–2028 (USD MILLION)

8.9 OTHER SURGICAL APPLICATIONS

TABLE 61 HEMOSTATS MARKET FOR OTHER SURGICAL APPLICATIONS, BY
REGION, 2018–2021 (USD MILLION)

TABLE 62 HEMOSTATS MARKET FOR OTHER SURGICAL APPLICATIONS, BY
REGION, 2022–2028 (USD MILLION)

9 HEMOSTATS MARKET, BY REGION

9.1 INTRODUCTION

TABLE 63 HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 64 HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)

9.2 NORTH AMERICA

FIGURE 26 NORTH AMERICA: HEMOSTATS MARKET SNAPSHOT

TABLE 65 NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2018–2021
(USD MILLION)

TABLE 66 NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2022–2028

(USD MILLION)

TABLE 67 NORTH AMERICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 68 NORTH AMERICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

TABLE 69 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION)

TABLE 70 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION)

TABLE 71 NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION)

TABLE 72 NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION)

9.2.1 NORTH AMERICA: RECESSION IMPACT

9.2.2 US

9.2.2.1 Strong healthcare infrastructure to support uptake of hemostats

TABLE 73 US: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 74 US: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.2.3 CANADA

9.2.3.1 Growing geriatric population and increasing volume of surgeries to drive demand for hemostats

TABLE 75 SURGICAL PROCEDURES PERFORMED IN CANADA, 2021

TABLE 76 CANADA: KEY MACROINDICATORS

TABLE 77 CANADA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 78 CANADA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3 EUROPE

TABLE 79 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION)

TABLE 80 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2022–2028 (USD MILLION)

TABLE 81 EUROPE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 82 EUROPE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

TABLE 83 EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION)

TABLE 84 EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION)

TABLE 85 EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION)

TABLE 86 EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD

MILLION)

9.3.1 EUROPE: RECESSION IMPACT

9.3.2 GERMANY

9.3.2.1 High healthcare expenditure in Germany to favor market growth

TABLE 87 SURGICAL PROCEDURES PERFORMED IN GERMANY, 2021

TABLE 88 GERMANY: KEY MACROINDICATORS

TABLE 89 GERMANY: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 90 GERMANY: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.3 UK

9.3.3.1 Growing volume of hernia repair and cardiovascular surgeries to drive market growth

TABLE 91 SURGICAL PROCEDURES PERFORMED IN UK, 2021

TABLE 92 UK: KEY MACROINDICATORS

TABLE 93 UK: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 94 UK: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.4 FRANCE

9.3.4.1 Presence of well-established healthcare system to propel market growth

TABLE 95 SURGICAL PROCEDURES PERFORMED IN FRANCE, 2021

TABLE 96 FRANCE: KEY MACROINDICATORS

TABLE 97 FRANCE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 98 FRANCE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.5 ITALY

9.3.5.1 Increasing volume of surgeries to drive demand for hemostats

TABLE 99 SURGICAL PROCEDURES PERFORMED IN ITALY, 2021

TABLE 100 ITALY: KEY MACROINDICATORS

TABLE 101 ITALY: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 102 ITALY: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.6 SPAIN

9.3.6.1 Growing healthcare budget and rising efforts to boost local manufacturing of medical products to drive market growth

TABLE 103 SURGICAL PROCEDURES PERFORMED IN SPAIN, 2021

TABLE 104 SPAIN: KEY MACROINDICATORS

TABLE 105 SPAIN: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 106 SPAIN: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.7 RUSSIA

9.3.7.1 Long-term healthcare investment initiatives by government to support market growth

TABLE 107 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 108 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.8 SWITZERLAND

9.3.8.1 Increasing public health insurance coverage to drive number of surgical procedures

TABLE 109 SURGICAL PROCEDURES PERFORMED IN SWITZERLAND, 2021

TABLE 110 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 111 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.9 BELGIUM

9.3.9.1 Increasing demand for value-based healthcare services to drive market growth

TABLE 112 SURGICAL PROCEDURES PERFORMED IN BELGIUM, 2021

TABLE 113 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 114 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.10 REST OF EUROPE

TABLE 115 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY

TABLE 116 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 117 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4 ASIA PACIFIC

FIGURE 27 ASIA PACIFIC: HEMOSTATS MARKET SNAPSHOT

TABLE 118 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION)

TABLE 119 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2022–2028 (USD MILLION)

TABLE 120 ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 121 ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

TABLE 122 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION)

TABLE 123 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION)

TABLE 124 ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION)

TABLE 125 ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION)

9.4.1 ASIA PACIFIC: RECESSION IMPACT

9.4.2 CHINA

9.4.2.1 Growing number of hospitals and healthcare policy reforms to drive growth

TABLE 126 CHINA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 127 CHINA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.3 JAPAN

9.4.3.1 Strong healthcare system and rising geriatric population to support market growth

TABLE 128 JAPAN: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 129 JAPAN: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.4 INDIA

9.4.4.1 Rising healthcare awareness and favorable government support to propel market growth

TABLE 130 INDIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 131 INDIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.5 AUSTRALIA

9.4.5.1 Rising prevalence of chronic diseases to drive market growth

TABLE 132 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 133 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.6 SOUTH KOREA

9.4.6.1 Growing number of cosmetic surgeries to drive demand for hemostats

TABLE 134 SURGICAL PROCEDURES IN SOUTH KOREA, 2021

TABLE 135 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 136 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.7 SINGAPORE

9.4.7.1 Government initiatives to promote healthcare services to support market growth

TABLE 137 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 138 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.8 NEW ZEALAND

9.4.8.1 Increasing number of hip fractures to propel market growth

TABLE 139 NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 140 NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.9 INDONESIA

9.4.9.1 Lucrative growth opportunities for players to boost market

TABLE 141 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 142 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.10 MALAYSIA

9.4.10.1 Low healthcare costs, modern medical technology, and highly qualified doctors to favor market growth

TABLE 143 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 144 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.11 REST OF ASIA PACIFIC

TABLE 145 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 146 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.5 LATIN AMERICA

TABLE 147 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION)

TABLE 148 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2022–2028 (USD MILLION)

TABLE 149 LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 150 LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

TABLE 151 LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION)

TABLE 152 LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION)

TABLE 153 LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION)

TABLE 154 LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION)

9.5.1 LATIN AMERICA: RECESSION IMPACT

9.5.2 BRAZIL

9.5.2.1 Brazil to dominate Latin American market for hemostats

TABLE 155 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 156 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.5.3 MEXICO

9.5.3.1 Low-cost surgeries to drive medical tourism in Mexico

TABLE 157 MEXICO: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 158 MEXICO: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.5.4 REST OF LATIN AMERICA

TABLE 159 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 160 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.6 MIDDLE EAST & AFRICA

9.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH

TABLE 161 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 162 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

TABLE 163 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION)

TABLE 164 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION)

TABLE 165 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION)

TABLE 166 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION)

9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMOSTATS MARKET

TABLE 167 OVERVIEW OF STRATEGIES DEPLOYED BY KEY HEMOSTAT MANUFACTURING COMPANIES

10.3 REVENUE ANALYSIS

FIGURE 28 REVENUE ANALYSIS OF TOP PLAYERS IN HEMOSTATS MARKET

(2018–2022)

10.4 MARKET SHARE ANALYSIS

FIGURE 29 MARKET SHARE ANALYSIS OF TOP PLAYERS IN HEMOSTATS MARKET (2022)

TABLE 168 HEMOSTATS MARKET: DEGREE OF COMPETITION

10.5 COMPANY EVALUATION MATRIX

10.5.1 LIST OF EVALUATED VENDORS

10.5.2 STARS

10.5.3 EMERGING LEADERS

10.5.4 PERVASIVE PLAYERS

10.5.5 PARTICIPANTS

FIGURE 30 HEMOSTATS MARKET: COMPANY EVALUATION MATRIX (2022)

10.5.6 COMPANY FOOTPRINT

10.5.6.1 Product & regional footprint analysis

FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN HEMOSTATS MARKET

TABLE 169 HEMOSTATS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS

TABLE 170 COMPANY FOOTPRINT, BY TYPE

TABLE 171 COMPANY FOOTPRINT, BY REGION

10.6 START-UP/SME EVALUATION MATRIX

10.6.1 PROGRESSIVE COMPANIES

10.6.2 RESPONSIVE COMPANIES

10.6.3 DYNAMIC COMPANIES

10.6.4 STARTING BLOCKS

FIGURE 32 HEMOSTATS MARKET: START-UP/SME EVALUATION MATRIX (2022)

10.7 COMPETITIVE SCENARIO

10.7.1 PRODUCT LAUNCHES & APPROVALS

TABLE 172 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2018–OCTOBER 2023)

10.7.2 DEALS

TABLE 173 KEY DEALS (JANUARY 2018–OCTOBER 2023)

10.7.3 OTHER KEY DEVELOPMENTS

TABLE 174 OTHER KEY DEVELOPMENTS (JANUARY 2018–OCTOBER 2023)

11 COMPANY PROFILES

(Business overview, Products offered, Recent developments & MnM View)*

11.1 KEY PLAYERS

11.1.1 JOHNSON & JOHNSON

TABLE 175 JOHNSON & JOHNSON: BUSINESS OVERVIEW

FIGURE 33 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)

11.1.2 BAXTER INTERNATIONAL

TABLE 176 BAXTER INTERNATIONAL: BUSINESS OVERVIEW

FIGURE 34 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2022)

11.1.3 PFIZER INC.

TABLE 177 PFIZER INC.: BUSINESS OVERVIEW

FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2022)

11.1.4 B. BRAUN SE

TABLE 178 B. BRAUN SE: BUSINESS OVERVIEW

FIGURE 36 B. BRAUN SE: COMPANY SNAPSHOT (2022)

11.1.5 BECTON, DICKINSON AND COMPANY

TABLE 179 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW

FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)

11.1.6 TELEFLEX INCORPORATED

TABLE 180 TELEFLEX INCORPORATED: BUSINESS OVERVIEW

FIGURE 38 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2022)

11.1.7 MEDTRONIC PLC

TABLE 181 MEDTRONIC PLC: BUSINESS OVERVIEW

FIGURE 39 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)

11.1.8 HEMOSTASIS, LLC

TABLE 182 HEMOSTASIS, LLC: BUSINESS OVERVIEW

11.1.9 STRYKER CORPORATION

TABLE 183 STRYKER CORPORATION: BUSINESS OVERVIEW

FIGURE 40 STRYKER CORPORATION: COMPANY SNAPSHOT (2022)

11.1.10 INTEGRA LIFESCIENCES

TABLE 184 INTEGRA LIFESCIENCES: BUSINESS OVERVIEW

FIGURE 41 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2022)

11.1.11 ADVANCED MEDICAL SOLUTIONS GROUP PLC

TABLE 185 ADVANCED MEDICAL SOLUTIONS GROUP PLC: BUSINESS OVERVIEW

FIGURE 42 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY SNAPSHOT (2022)

11.1.12 SAMYANG HOLDINGS CORPORATION

TABLE 186 SAMYANG CORPORATION: BUSINESS OVERVIEW

FIGURE 43 SAMYANG CORPORATION: COMPANY SNAPSHOT (2022)

*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.

11.2 OTHER PLAYERS

11.2.1 MARINE POLYMER TECHNOLOGIES, INC.

11.2.2 GELITA MEDICAL GMBH

11.2.3 DILON TECHNOLOGIES, INC.

11.2.4 BETATECH MEDICAL

11.2.5 MERIL LIFE SCIENCES PVT. LTD.

11.2.6 BIOCER ENTWICKLUNGS-GMBH

11.2.7 UNILENE

11.2.8 KATSAN MEDICAL DEVICES

11.2.9 TRICOL BIOMEDICAL

11.2.10 3-D MATRIX MEDICAL TECHNOLOGY

11.2.11 HEMOSTAT MEDICAL GMBH

11.2.12 MEDTRADE PRODUCTS LIMITED

11.2.13 ALTAYLAR MEDICAL

12 APPENDIX

12.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

12.2 CUSTOMIZATION OPTIONS

12.3 RELATED REPORTS

12.4 AUTHOR DETAILS

I would like to order

Product name: Hemostats Market by Type (Thrombin, Oxidized Regenerated Cellulose, Combination, Gelatin, Collagen), Formulation (Matrix & Gel, Sheet & Pad, Sponge, Powder), Application (Orthopedic, Neurological, Cardiovascular Surgery), Region - Global Forecast to 2028

Product link: <https://marketpublishers.com/r/H21D40D9390EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H21D40D9390EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970